Physician profile
Subhas Sitaula
NPI 1104175546
$10,017.23
in general payments reported to CMS, 2019-2025
36 companies · $762 in 2025
The $762 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $789 · 2021: $987 · 2022: $1,731 · 2023: $571 · 2024: $3,957 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,584 · Food and Beverage: $1,742 · Travel and Lodging: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,583.74 |
| Food and Beverage | $1,741.63 |
| Travel and Lodging | $964.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,598.18 | 2023-2024 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $1,718.13 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pulmonx Corporation | $1,131.31 | 2019-2025 | Chartis Catheter, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Ethicon INC. | $698.16 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $470.17 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.87 | 2019-2025 | Ofev, Jascayd |
| United Therapeutics Corporation | $267.02 | 2019-2025 | Tyvaso, Tyvaso |
| Astrazeneca Pharmaceuticals LP | $232.08 | 2019-2025 | Fasenra, Tezspire |
| Insmed, INC. | $185.59 | 2019-2025 | Arikayce |
| Genentech USA, INC. | $127.00 | 2019-2022 | |
| Grifols USA, LLC | $121.29 | 2019-2020 | |
| Steris Corporation | $117.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $115.02 | 2019-2022 | |
| Electromed, INC. | $94.68 | 2022-2025 | Smartvest |
| Takeda Pharmaceuticals U.S.A., INC. | $88.74 | 2020-2025 | Glassia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $81.88 | 2019 | |
| Merck Sharp & Dohme LLC | $65.01 | 2021-2024 | Winrevair |
| Astellas Pharma US INC | $63.54 | 2024-2025 | Cresemba |
| Mylan Specialty L.P. | $59.83 | 2019-2023 | Yupelri |
| Abiomed | $56.77 | 2022 | |
| Genzyme Corporation | $54.46 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $51.08 | 2019-2023 | Dupixent |
| Advanced Respiratory, INC | $43.16 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $39.11 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.91 | 2020-2023 | |
| La Jolla Pharmaceutical Company | $34.33 | 2020 | |
| Shire North American Group INC | $27.69 | 2019 | |
| Lungpacer Medical USA INC | $27.21 | 2025 | Aeropace Neurostimulation Console |
| Ani Pharmaceuticals, INC. | $19.00 | 2024 | Purified Cortrophin Gel |
| Paratek Pharmaceuticals, INC. | $18.81 | 2020 | |
| Viatris Specialty LLC | $18.31 | 2025 | Yupelri |
| Circassia INC. | $17.50 | 2019 | |
| Portola Pharmaceuticals, LLC | $15.16 | 2020 | |
| Apria Healthcare LLC | $14.01 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.78 | 2020 | |
| Ucb, INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhas Sitaula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.